加替沙星（BMS-284756）对9种巴斯德菌属170株临床分离株的体外活性
In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species.
作者信息
Goldstein Ellie J C, Citron Diane M, Merriam C Vreni, Warren Yumi A, Tyrrell Kerin L, Fernandez Helen T
机构信息
R. M. Alden Research Laboratory, Santa Monica-University of California, Los Angeles, Medical Center, Santa Monica, California 90404, USA.
出版信息
Antimicrob Agents Chemother. 2002 Sep;46(9):3068-70. doi: 10.1128/AAC.46.9.3068-3070.2002.
Abstract
The in vitro susceptibilities of 170 clinical isolates plus 12 American Type Culture Collection strains of Pasteurella species comprising nine species and three Pasteurella multocida subspecies were studied by an agar dilution method. Garenoxacin (BMS-284756), a new des-fluoro(6) quinolone, was active at <or=0.06 micro g/ml against all isolates, including four beta-lactamase-producing strains, with >90% of the strains susceptible to <or=0.008 micro g/ml. Garenoxacin was generally 1 to 2 dilutions more active than levofloxacin and moxifloxacin and was the most active agent tested. Cefoxitin required 1 micro g/ml for inhibition of 51 of 182 (29%) of strains, and 3 strains (also beta-lactamase producers) were resistant to doxycycline.
摘要
采用琼脂稀释法研究了170株临床分离株以及12株美国典型培养物保藏中心的巴斯德菌属菌株（包括9个种和3个多杀巴斯德菌亚种）的体外药敏情况。新型去氟（6）喹诺酮类药物加替沙星（BMS - 284756）对所有分离株的活性均≤0.06μg/ml，包括4株产β-内酰胺酶的菌株，90%以上的菌株对≤0.008μg/ml的药物敏感。加替沙星的活性通常比左氧氟沙星和莫西沙星高1至2个稀释度，是所测试药物中活性最高的。头孢西丁抑制182株菌株中的51株（29%）需要1μg/ml的浓度，3株菌株（也是产β-内酰胺酶的菌株）对多西环素耐药。
相似文献
1
In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species.
Antimicrob Agents Chemother. 2002 Sep;46(9):3068-70. doi: 10.1128/AAC.46.9.3068-3070.2002.
2
Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
Antimicrob Agents Chemother. 2003 Mar;47(3):910-6. doi: 10.1128/AAC.47.3.910-916.2003.
3
In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
Antimicrob Agents Chemother. 2002 Mar;46(3):866-70. doi: 10.1128/AAC.46.3.866-870.2002.
4
Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
Diagn Microbiol Infect Dis. 2002 Oct;44(2):187-94. doi: 10.1016/s0732-8893(02)00433-9.
5
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
Diagn Microbiol Infect Dis. 2002 Aug;43(4):303-9. doi: 10.1016/s0732-8893(02)00415-7.
6
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
7
In vitro activities of a new des-fluoroquinolone, BMS 284756, and seven other antimicrobial agents against 151 isolates of Eikenella corrodens.
Antimicrob Agents Chemother. 2002 Apr;46(4):1141-3. doi: 10.1128/AAC.46.4.1141-1143.2002.
8
In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.
Antimicrob Agents Chemother. 2002 Dec;46(12):3995-6. doi: 10.1128/AAC.46.12.3995-3996.2002.
9
[Comparative study of the bacteriostatic and bactericidal activity of levofloxacin against Pasteurella strains isolated from man].
Pathol Biol (Paris). 2001 Oct;49(8):606-11. doi: 10.1016/s0369-8114(01)00216-4.
10
Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus.
J Antimicrob Chemother. 2002 Feb;49(2):283-7. doi: 10.1093/jac/49.2.283.
引用本文的文献
1
Pasteurella multocida bacteremia: A case report of pelvic cavity inflammation with abnormal uterine bleeding, fever, and sclerotic bone lesions.
IDCases. 2023 Feb 17;31:e01723. doi: 10.1016/j.idcr.2023.e01723. eCollection 2023.
2
Pet-related Pasteurella multocida induced peritonitis in peritoneal dialysis: a case report and review of the literatures.
BMC Nephrol. 2020 Mar 19;21(1):102. doi: 10.1186/s12882-020-01765-1.
3
Antimicrobial Resistance in of Veterinary Origin.
Microbiol Spectr. 2018 May;6(3). doi: 10.1128/microbiolspec.ARBA-0022-2017.
4
Fatal multifocal Pasteurella multocida infection: a case report.
BMC Res Notes. 2015 Jul 2;8:287. doi: 10.1186/s13104-015-1232-7.
5
Moxifloxacin in the treatment of skin and skin structure infections.
Ther Clin Risk Manag. 2006 Dec;2(4):417-34. doi: 10.2147/tcrm.2006.2.4.417.
6
Broth microdilution and disk diffusion tests for susceptibility testing of Pasteurella species isolated from human clinical specimens.
J Clin Microbiol. 2005 May;43(5):2485-8. doi: 10.1128/JCM.43.5.2485-2488.2005.
本文引用的文献
1
In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
Antimicrob Agents Chemother. 2002 Mar;46(3):866-70. doi: 10.1128/AAC.46.3.866-870.2002.
2
Pasteurella multocida subsp. multocida and P. multocida subsp. septica differentiation by PCR fingerprinting and alpha-glucosidase activity.
J Clin Microbiol. 2001 Jul;39(7):2558-64. doi: 10.1128/JCM.39.7.2558-2564.2001.
3
Comparative antianaerobic activity of BMS 284756.
Antimicrob Agents Chemother. 2001 Feb;45(2):589-92. doi: 10.1128/AAC.45.2.589-592.2001.
4
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.
Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6. doi: 10.1128/AAC.44.12.3351-3356.2000.
5
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.
Antimicrob Agents Chemother. 1999 May;43(5):1077-84. doi: 10.1128/AAC.43.5.1077.
6
Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group.
N Engl J Med. 1999 Jan 14;340(2):85-92. doi: 10.1056/NEJM199901143400202.
7
New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds.
J Med Microbiol. 1998 Feb;47(2):95-7. doi: 10.1099/00222615-47-2-95.
8
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
J Antimicrob Chemother. 1998 Mar;41(3):391-6. doi: 10.1093/jac/41.3.391.
9
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
Antimicrob Agents Chemother. 1997 Jul;41(7):1552-7. doi: 10.1128/AAC.41.7.1552.
10
Distribution of indole-producing urease-negative pasteurellas in animals.
J Vet Diagn Invest. 1991 Oct;3(4):319-23. doi: 10.1177/104063879100300408.
Zotero 插件